Flossbach Von Storch SE Cuts Position in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Flossbach Von Storch SE reduced its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 3.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,259,631 shares of the company's stock after selling 147,212 shares during the period. BioNTech accounts for approximately 1.7% of Flossbach Von Storch SE's investment portfolio, making the stock its 21st biggest position. Flossbach Von Storch SE owned approximately 1.78% of BioNTech worth $387,882,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in BioNTech by 18,892.9% during the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after acquiring an additional 694,691 shares during the period. GF Fund Management CO. LTD. grew its holdings in BioNTech by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company's stock worth $229,000 after acquiring an additional 453 shares during the period. OneDigital Investment Advisors LLC acquired a new stake in BioNTech during the 1st quarter worth about $288,000. Vontobel Holding Ltd. grew its holdings in BioNTech by 2.3% during the 1st quarter. Vontobel Holding Ltd. now owns 21,882 shares of the company's stock worth $1,993,000 after acquiring an additional 497 shares during the period. Finally, Goodman Advisory Group LLC acquired a new stake in BioNTech during the 1st quarter worth about $105,000. 15.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Leerink Partners set a $112.00 price target on BioNTech in a report on Monday, June 2nd. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. HC Wainwright restated a "buy" rating and issued a $138.00 target price on shares of BioNTech in a research note on Wednesday, June 25th. Morgan Stanley set a $133.00 target price on BioNTech and gave the company an "overweight" rating in a research note on Thursday. Finally, Truist Financial restated a "buy" rating and issued a $155.00 target price (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and an average price target of $137.91.

BioNTech Stock Up 1.9%

BNTX stock traded up $2.14 during mid-day trading on Thursday, reaching $113.92. 667,934 shares of the company traded hands, compared to its average volume of 944,121. The stock has a market cap of $27.39 billion, a price-to-earnings ratio of -33.51 and a beta of 1.29. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm's 50 day moving average price is $103.40 and its 200 day moving average price is $106.86.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.